Cargando…

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium

AIMS/HYPOTHESIS: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarke...

Descripción completa

Detalles Bibliográficos
Autores principales: Koivula, Robert W., Heggie, Alison, Barnett, Anna, Cederberg, Henna, Hansen, Tue H., Koopman, Anitra D., Ridderstråle, Martin, Rutters, Femke, Vestergaard, Henrik, Gupta, Ramneek, Herrgård, Sanna, Heymans, Martijn W., Perry, Mandy H., Rauh, Simone, Siloaho, Maritta, Teare, Harriet J. A., Thorand, Barbara, Bell, Jimmy, Brunak, Søren, Frost, Gary, Jablonka, Bernd, Mari, Andrea, McDonald, Tim J., Dekker, Jacqueline M., Hansen, Torben, Hattersley, Andrew, Laakso, Markku, Pedersen, Oluf, Koivisto, Veikko, Ruetten, Hartmut, Walker, Mark, Pearson, Ewan, Franks, Paul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018481/
https://www.ncbi.nlm.nih.gov/pubmed/24695864
http://dx.doi.org/10.1007/s00125-014-3216-x
_version_ 1782480074006593536
author Koivula, Robert W.
Heggie, Alison
Barnett, Anna
Cederberg, Henna
Hansen, Tue H.
Koopman, Anitra D.
Ridderstråle, Martin
Rutters, Femke
Vestergaard, Henrik
Gupta, Ramneek
Herrgård, Sanna
Heymans, Martijn W.
Perry, Mandy H.
Rauh, Simone
Siloaho, Maritta
Teare, Harriet J. A.
Thorand, Barbara
Bell, Jimmy
Brunak, Søren
Frost, Gary
Jablonka, Bernd
Mari, Andrea
McDonald, Tim J.
Dekker, Jacqueline M.
Hansen, Torben
Hattersley, Andrew
Laakso, Markku
Pedersen, Oluf
Koivisto, Veikko
Ruetten, Hartmut
Walker, Mark
Pearson, Ewan
Franks, Paul W.
author_facet Koivula, Robert W.
Heggie, Alison
Barnett, Anna
Cederberg, Henna
Hansen, Tue H.
Koopman, Anitra D.
Ridderstråle, Martin
Rutters, Femke
Vestergaard, Henrik
Gupta, Ramneek
Herrgård, Sanna
Heymans, Martijn W.
Perry, Mandy H.
Rauh, Simone
Siloaho, Maritta
Teare, Harriet J. A.
Thorand, Barbara
Bell, Jimmy
Brunak, Søren
Frost, Gary
Jablonka, Bernd
Mari, Andrea
McDonald, Tim J.
Dekker, Jacqueline M.
Hansen, Torben
Hattersley, Andrew
Laakso, Markku
Pedersen, Oluf
Koivisto, Veikko
Ruetten, Hartmut
Walker, Mark
Pearson, Ewan
Franks, Paul W.
author_sort Koivula, Robert W.
collection PubMed
description AIMS/HYPOTHESIS: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT. METHODS: Prediabetic participants (target sample size 2,200–2,700) and patients with newly diagnosed type 2 diabetes (target sample size ~1,000) are undergoing detailed metabolic phenotyping at baseline and 18 months and 36 months later. Abdominal, pancreatic and liver fat is assessed using MRI. Insulin secretion and action are assessed using frequently sampled OGTTs in non-diabetic participants, and frequently sampled mixed-meal tolerance tests in patients with type 2 diabetes. Biosamples include venous blood, faeces, urine and nail clippings, which, among other biochemical analyses, will be characterised at genetic, transcriptomic, metabolomic, proteomic and metagenomic levels. Lifestyle is assessed using high-resolution triaxial accelerometry, 24 h diet record, and food habit questionnaires. CONCLUSIONS/INTERPRETATION: DIRECT will yield an unprecedented array of biomaterials and data. This resource, available through managed access to scientists within and outside the Consortium, will facilitate the development of new treatments and therapeutic strategies for the prevention and management of type 2 diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-014-3216-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-4018481
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-40184812014-05-13 Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium Koivula, Robert W. Heggie, Alison Barnett, Anna Cederberg, Henna Hansen, Tue H. Koopman, Anitra D. Ridderstråle, Martin Rutters, Femke Vestergaard, Henrik Gupta, Ramneek Herrgård, Sanna Heymans, Martijn W. Perry, Mandy H. Rauh, Simone Siloaho, Maritta Teare, Harriet J. A. Thorand, Barbara Bell, Jimmy Brunak, Søren Frost, Gary Jablonka, Bernd Mari, Andrea McDonald, Tim J. Dekker, Jacqueline M. Hansen, Torben Hattersley, Andrew Laakso, Markku Pedersen, Oluf Koivisto, Veikko Ruetten, Hartmut Walker, Mark Pearson, Ewan Franks, Paul W. Diabetologia Article AIMS/HYPOTHESIS: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT. METHODS: Prediabetic participants (target sample size 2,200–2,700) and patients with newly diagnosed type 2 diabetes (target sample size ~1,000) are undergoing detailed metabolic phenotyping at baseline and 18 months and 36 months later. Abdominal, pancreatic and liver fat is assessed using MRI. Insulin secretion and action are assessed using frequently sampled OGTTs in non-diabetic participants, and frequently sampled mixed-meal tolerance tests in patients with type 2 diabetes. Biosamples include venous blood, faeces, urine and nail clippings, which, among other biochemical analyses, will be characterised at genetic, transcriptomic, metabolomic, proteomic and metagenomic levels. Lifestyle is assessed using high-resolution triaxial accelerometry, 24 h diet record, and food habit questionnaires. CONCLUSIONS/INTERPRETATION: DIRECT will yield an unprecedented array of biomaterials and data. This resource, available through managed access to scientists within and outside the Consortium, will facilitate the development of new treatments and therapeutic strategies for the prevention and management of type 2 diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-014-3216-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2014-04-04 2014 /pmc/articles/PMC4018481/ /pubmed/24695864 http://dx.doi.org/10.1007/s00125-014-3216-x Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Article
Koivula, Robert W.
Heggie, Alison
Barnett, Anna
Cederberg, Henna
Hansen, Tue H.
Koopman, Anitra D.
Ridderstråle, Martin
Rutters, Femke
Vestergaard, Henrik
Gupta, Ramneek
Herrgård, Sanna
Heymans, Martijn W.
Perry, Mandy H.
Rauh, Simone
Siloaho, Maritta
Teare, Harriet J. A.
Thorand, Barbara
Bell, Jimmy
Brunak, Søren
Frost, Gary
Jablonka, Bernd
Mari, Andrea
McDonald, Tim J.
Dekker, Jacqueline M.
Hansen, Torben
Hattersley, Andrew
Laakso, Markku
Pedersen, Oluf
Koivisto, Veikko
Ruetten, Hartmut
Walker, Mark
Pearson, Ewan
Franks, Paul W.
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium
title Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium
title_full Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium
title_fullStr Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium
title_full_unstemmed Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium
title_short Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium
title_sort discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the imi direct consortium
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018481/
https://www.ncbi.nlm.nih.gov/pubmed/24695864
http://dx.doi.org/10.1007/s00125-014-3216-x
work_keys_str_mv AT koivularobertw discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT heggiealison discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT barnettanna discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT cederberghenna discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT hansentueh discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT koopmananitrad discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT ridderstralemartin discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT ruttersfemke discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT vestergaardhenrik discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT guptaramneek discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT herrgardsanna discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT heymansmartijnw discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT perrymandyh discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT rauhsimone discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT siloahomaritta discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT teareharrietja discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT thorandbarbara discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT belljimmy discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT brunaksøren discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT frostgary discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT jablonkabernd discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT mariandrea discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT mcdonaldtimj discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT dekkerjacquelinem discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT hansentorben discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT hattersleyandrew discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT laaksomarkku discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT pedersenoluf discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT koivistoveikko discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT ruettenhartmut discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT walkermark discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT pearsonewan discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT frankspaulw discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium
AT discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesrationaleanddesignoftheepidemiologicalstudieswithintheimidirectconsortium